Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers
Authors
Keywords
-
Journal
Breast Cancer
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-16
DOI
10.1007/s12282-019-00977-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer
- (2018) Erik J. Blok et al. BREAST CANCER RESEARCH AND TREATMENT
- Checkpoint blockade in the treatment of breast cancer: current status and future directions
- (2018) Lironne Wein et al. BRITISH JOURNAL OF CANCER
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
- (2017) Stephen J. Luen et al. PATHOLOGY
- Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
- (2016) Akira I. Hida et al. BREAST CANCER RESEARCH AND TREATMENT
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients
- (2015) Fausto Petrelli et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis
- (2014) Yan Mao et al. PLoS One
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
- (2013) A. K. Dunbier et al. CLINICAL CANCER RESEARCH
- Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients – an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pathobiological response of the patients
- (2013) Monica SM Chan et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
- (2009) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More